Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
The primary objective was to assess the effect of SR141716 on weight loss and weight
maintenance over a period of one year when prescribed with a hypocaloric diet in obese
patients with or without comorbidities.
The main secondary objectives were to assess the effect of SR141716 on lipid parameters
(HDL-C, TG), glucose tolerance status, the rate of patients with metabolic syndrome, waist
circumference, glycemic parameters.